5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
-11.1%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$447M
AUM Growth
+$447M
(+0.1%)
Cap. Flow
+$27.2M
Cap. Flow
% of AUM
6.07%
Top 10 Holdings %
Top 10 Hldgs %
73.55%
Holding
30
New
4
Increased
1
Reduced
3
Closed
2
Top Buys
| 1 |
Skye Bioscience
SKYE
|
$81.5M |
| 2 |
Erasca
ERAS
|
$12.8M |
| 3 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$10.6M |
| 4 |
Biohaven
BHVN
|
$5.21M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$435K |
Top Sells
| 1 |
Enliven Therapeutics
ELVN
|
$28.6M |
| 2 |
Merus
MRUS
|
$24.7M |
| 3 |
Avidity Biosciences
RNA
|
$17M |
| 4 |
Cidara Therapeutics
CDTX
|
$12.9M |
| 5 |
Dianthus Therapeutics
DNTH
|
$235K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Skye Bioscience
SKYE
$108M
| $81.5M | 18.24% | +10,179,505 | New | +$81.5M |
|
2
Entrada Therapeutics
TRDA
$208M
| $62.8M | 14.05% | 4,408,379 | – | – |
|
|
3
Enliven Therapeutics
ELVN
$1.2B
| $61M | 13.65% | 2,610,875 -1,225,100 | -32% | -$28.6M |
|
|
4
Dianthus Therapeutics
DNTH
$759M
| $31.9M | 7.14% | 1,232,965 -9,064 | -0.7% | -$235K |
|
5
Celldex Therapeutics
CLDX
$1.47B
| $18.4M | 4.12% | 497,270 | – | – |
|
|
6
Biohaven
BHVN
$1.63B
| $16.3M | 3.65% | 469,972 +150,000 | +47% | +$5.21M |
|
7
Tyra Biosciences
TYRA
$675M
| $15M | 3.36% | 939,298 | – | – |
|
8
Pharvaris
PHVS
$1.39B
| $15M | 3.35% | 797,600 | – | – |
|
9
Praxis Precision Medicines
PRAX
$958M
| $14.1M | 3.15% | 340,000 | – | – |
|
|
10
Erasca
ERAS
$445M
| $12.8M | 2.85% | +5,405,404 | New | +$12.8M |
|
11
Viking Therapeutics
VKTX
$3.04B
| $12.6M | 2.82% | 237,560 | – | – |
|
12
MoonLake Immunotherapeutics
MLTX
$3.54B
| $12.4M | 2.78% | 282,313 | – | – |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $11.2M | 2.51% | 1,245,000 | – | – |
|
|
TECX
14
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $10.6M | 2.38% | +646,524 | New | +$10.6M |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $9.58M | 2.14% | 736,595 | – | – |
|
|
SLN
16
Silence Therapeutics
SLN
$227M
| $9.05M | 2.02% | 476,200 | – | – |
|
17
AnaptysBio
ANAB
$569M
| $8.96M | 2.01% | 357,733 | – | – |
|
18
GH Research
GHRS
$837M
| $6.68M | 1.49% | 572,665 | – | – |
|
19
Cogent Biosciences
COGT
$1.69B
| $6.66M | 1.49% | 790,440 | – | – |
|
20
Vor Biopharma
VOR
$250M
| $6.36M | 1.42% | 6,361,723 | – | – |
|
21
scPharmaceuticals
SCPH
$295M
| $5.22M | 1.17% | 1,200,647 | – | – |
|
22
Rallybio
RLYB
$22.4M
| $4.87M | 1.09% | 3,630,724 | – | – |
|
23
Q32 Bio
QTTB
$20.9M
| $4.52M | 1.01% | 251,994 | – | – |
|
24
Adverum Biotechnologies
ADVM
$64.6M
| $3.72M | 0.83% | 541,666 | – | – |
|
25
Mersana Therapeutics
MRSN
$36.5M
| $2.62M | 0.59% | 1,305,000 | – | – |
|